在怀孕期间药物治疗的资源和药物信息
概括
本综述概述了医疗保健专业人员在怀孕期间使用药物的资源. 它强调了一种全面的,基于证据的方法,为母亲和胎儿提供安全的药物治疗.
科学领域:
- 药理学 药理学是指药理学的学科.
- 孕产妇和胎儿医学 孕产妇和胎儿医学
- 基于证据的医学基于证据的医学.
背景情况:
- 怀孕需要对母亲和胎儿的药物安全性和疗效进行仔细评估.
- 产品信息摘要往往提供有限的指导,导致处方过度谨慎.
- 在怀孕期间使用药物的可靠信息对于明智的临床决策至关重要.
研究的目的:
- 为孕妇使用药物的专业信息资源提供叙事概述.
- 引导医疗保健专业人员为这一群体选择和评估药物.
主要方法:
- 对现有文献和专业资源进行叙述性审查.
- 识别和分类有关怀孕期药物治疗的信息来源.
主要成果:
- 资源包括国家/国际专著,生物医学数据库,临床指南和专门的网页.
- 药物不良反应数据库,病理学信息服务和先天性异常登记册也是关键资源.
- 审查强调了多学科和基于证据的方法的重要性.
结论:
- 医疗保健专业人员应系统地利用各种信息来源,在怀孕期间进行药物管理.
- 多学科合作和基于证据的原则对于安全有效的药物治疗干预措施至关重要.
- 综合性方法可确保为服用药物的孕妇提供最佳护理.
相关概念视频
Drug Therapy
232
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
232
Factors Affecting Drug Response: Overview
2.8K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.8K
Drug Administration and Therapy Phases: Overview
1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
Drug Dosing: Infants and Children
231
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
231
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
229
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
229
Pharmacokinetics in Pediatric Patients: Drug Excretion
194
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
194


